Key result
Systemic chemotherapy with liposomal doxorubicin resulted in a complete clinical response in a patient with metastatic epithelioid angiosarcoma of the heart, remaining disease-free at 48 months.
Why the study?
Does liposomal doxorubicin improve clinical response and survival in a patient with metastatic epithelioid angiosarcoma of the heart?
Case Report (n=1)
Does liposomal doxorubicin improve clinical response and survival in a patient with metastatic epithelioid angiosarcoma of the heart?
Liposomal doxorubicin may be an effective treatment for metastatic epithelioid angiosarcoma of the heart, leading to prolonged disease-free survival.
Answers are grounded in this paper and cite their sources.
May support liposomal doxorubicin in metastatic cardiac angiosarcoma; hypothesis-generating and requires prospective validation.
Angiosarcoma is the most common primary malignant tumour of the heart. It is a rare and aggressive neoplasm that almost always has a short and fatal evolution. By the time it produces symptoms it has usually progressed to a mass causing haemodynamic compromise. Initial presentation with metastatic disease is unusual. We report the case of a 72-year-old man who presented with painful skin lesions on both hands. The skin biopsy was diagnosed as intravascular metastasis of epithelioid angiosarcoma. Body computed tomography scan disclosed a solid mass in the left atrium. The tumour was judged unresectable and the patient was treated with systemic chemotherapy, consisting of liposomal doxorubicin, which resulted in a complete clinical response. The patient remains free of disease after 48 months of follow-up. The excellent clinical evolution of our patient verifies that liposomal doxorubicin may be effective in the treatment of these tumours and significantly prolong patients' lifespan.
No takes yet. Share an insight, caveat, or question.
Candeias et al. (2010) conducted a case report in Metastatic epithelioid angiosarcoma of the heart (n=1). Liposomal doxorubicin was evaluated on Clinical response. Systemic chemotherapy with liposomal doxorubicin resulted in a complete clinical response in a patient with metastatic epithelioid angiosarcoma of the heart, remaining disease-free at 48 months.
Synapse has enriched 10 related papers. Consider them for comparative context: